Drugs / HNC042
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04603989 | Aug → Nov 2020 | influenza | Guangzhou Henovcom Bioscience Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03740555 | Nov 2018 → Jul 2019 | — | Guangzhou Henovcom Bioscience Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HNC042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04603989 ↗ |
| Route | Intravenous | “Intravenous route” NCT03740555 ↗ |